Date:7/20/2009

ire Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave or Empatic to delay or prevent regulatory approval or commercialization, or result in product liability claims, including serious adverse events that are not characterized by clinical investigators as possibly related to Contrave; the third parties on whom Orexigen relies to assist with the development programs for Contrave or Empatic, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; Orexigen may be unable to enter a collaboration or partnership relating to Contrave for promotion to broader markets on attractive terms or at all; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Information included herein is based on the Company's review and evaluation of the clinical data. All conclusions and determinations contained herein are
'/>"/>

SOURCE Orexigen Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Blacks Have Highest Obesity Rates in U.S.
2. Video: Sodexo Takes on Childhood Obesity in School Cafeterias
3. Obesity Contributes to Rapid Cartilage Loss
4. Obesity contributes to rapid cartilage loss
5. Childhood obesity link to parents
6. Study finds citrus-derived flavonoid prevents obesity
7. Is obesity an oral bacterial disease?
8. The Obesity Society Selects Executive Vice President
9. Obesity Rates Continue to Climb in U.S.
10. New Report Finds Obesity Epidemic Increases, Mississippi Weighs in as Heaviest State
11. Equine Obesity is Associated with Significant Health Issues, Including Insulin Resistance and Laminitis